A nasal spray developed by researchers from Chulalongkorn University which could help reduce the risk of catching Covid-19 will be available for the public to purchase starting on Oct 1.
The spray, which which will be sold under the brand name “VAILL CITITRAP Anti-Cov Nasal Spray”, is produced by Hibiocy, a subsidiary of the cosmetics conglomerate Rojukiss International.
Developed by a team of doctors and researchers from Chulalongkorn University’s Faculty of Medicine, the spray is truly a Thai innovation for Thai people, said Rojukiss CEO Worawarn Chaikamnerd.
The spray is designed to coat the user’s nasal cavities with a layer of hydroxypropyl methylcellulose, which acts as a physical barrier from the virus. It can be applied every six hours, up to three times a day.
Source: Chula University, Bangkok Post
